The practical consequences of the hypothesis that SIRT2 regulates genes encoding tyrosine kinase receptors and other signaling molecules that are critical for the function of the main signaling pathway targeted by dasatinib and V600E inhibitors [65,75] should be considered in light of new combination therapies for the treatment of melanoma. This evidence concerns the gene SIRT2 and melanoma.